Lotus Eye Hospital & Institute (BOM:532998) ROCE %: -0.82% (As of Mar. 2026)


BOM:532998 Lotus Eye Hospital & Institute Ltd BOM:532998
66 GF Score
Price ₹126.50
GF Value ₹91.88
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Lotus Eye Hospital & Institute ROCE %?

Lotus Eye Hospital & Institute BOM:532998 +5.90% 66 ROCE % is -0.82% as of Mar. 2026. GuruFocus rates BOM:532998 with a GF Score™ of 66/100 and a GF Value™ of ₹91.88 (Significantly Overvalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lotus Eye Hospital & Institute's annualized ROCE % for the quarter that ended in Mar. 2026 was -0.82%.

Lotus Eye Hospital & Institute  (BOM:532998) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lotus Eye Hospital & Institute ROCE % Related Terms

Lotus Eye Hospital & Institute ROCE % Historical Data

* Premium members only.

The historical data trend for Lotus Eye Hospital & Institute's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lotus Eye Hospital & Institute ROCE % Chart

Lotus Eye Hospital & Institute Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.73 10.10 6.95 2.84 1.19

Lotus Eye Hospital & Institute Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.03 5.45 1.24 -0.56 -0.82
BOM:532998
66GF Score
Lotus Eye Hospital & Institute Ltd BOM:532998
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lotus Eye Hospital & Institute ROCE % Calculation

Lotus Eye Hospital & Institute's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=8.056/( ( (695.737 - 74.246) + (825.974 - 93.433) )/ 2 )
=8.056/( (621.491+732.541)/ 2 )
=8.056/677.016
=1.19 %

Lotus Eye Hospital & Institute's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-6/( ( (0 - 0) + (825.974 - 93.433) )/ 1 )
=-6/( ( 0 + 732.541 )/ 1 )
=-6/732.541
=-0.82 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -0.82% mean?
Lotus Eye Hospital & Institute (BOM:532998) has a ROCE % of -0.82% as of Mar. 2026.
Is Lotus Eye Hospital & Institute's ROCE % too high?
Lotus Eye Hospital & Institute's current ROCE % is -0.82%. Overall, Lotus Eye Hospital & Institute has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lotus Eye Hospital & Institute's ROCE % compare to HCA and THC?
Lotus Eye Hospital & Institute's ROCE % of -0.82% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 646 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Eye Hospital & Institute's current ROCE % is -0.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Eye Hospital & Institute stock overvalued right now?
Based on GuruFocus' analysis, Lotus Eye Hospital & Institute (BOM:532998) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹91.88, compared to a current price of ₹126.50 — trading 37.7% above its estimated fair value. The current ROCE % is -0.82%. Lotus Eye Hospital & Institute's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Lotus Eye Hospital & Institute (BOM:532998), the current ROCE % is -0.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lotus Eye Hospital & Institute (BOM:532998) Overvalued in 2026?

Based on GuruFocus' analysis, Lotus Eye Hospital & Institute stock appears to be overvalued. The current stock price of ₹126.50 is trading 37.7% above its estimated GF Value™ of ₹91.88. GuruFocus considers Lotus Eye Hospital & Institute to be Significantly Overvalued.

Key valuation signals for BOM:532998:

  • ROCE %: -0.82%
  • GF Value™: ₹91.88 vs. price of ₹126.50 (37.7% above fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the BOM:532998 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lotus Eye Hospital & Institute Business Description

Other Exchanges LOTUSEYE:India
Address SF No. 770/12, Avinashi Road, Civil Aerodrome Post, Coimbatore, TN, IND, 641 014
Lotus Eye Hospital & Institute Ltd is an India-based eye care hospital. It is engaged in providing treatment and care for eye diseases and disorders. It offers treatment services for eye conditions like refractive error, retina and uvea, cornea, glaucoma, pediatric, orbit and oculoplasty, neuro-ophthalmology, and binocular vision. In addition, the company also operates an eye bank for functioning eye donation activities. The company mainly operates in India and generates revenue by providing medical services, pharmacy sales, contact lenses, and optical, of which the majority of the revenue is derived from providing segmmedical services.
66GF Score

Get the complete analysis for BOM:532998

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹126.50
Price
₹91.88
GF Value